关键词: 丙型肝炎肝硬化, 聚乙二醇化干扰素α, -2a, 利巴韦林, 治疗

Abstract: Objective To investigate the efficacy of combination of pegylated interferon-α-2a（peg-IFN-α2a） and ribavirin in treatment of patients with compensated hepatitis C cirrhosis. Methods 122 patients with compensated hepatitis C cirrhosis were recruited in our hospital between January 2003 and December 2016,and were divided randomly into control （n=61） and observation group （n=61）,receiving conventional therapy or peg-IFN-α2a and ribavirin combination for 24 to 48 weeks,respectively. All patients were followed-up for 24 weeks. Serum LN,PC Ⅲ and HA levels were assayed routinely,and liver stiffness measurement（LSM） was obtained by Fibroscan. Results At the end of the observation,serum HCV RNA load in patients receiving antiviral therapy was （2.0±0.4） lg IU/ml,much lower than 【（3.8±1.3）lg IU/ml,P<0.05】 in the control;serum AST and ALT levels were （46.03±24.05） U/L and （36.32±20.1） U/L,much lower than 【（78.7±21.1） U/L and（51.2±20.9） U/L,P<0.05）,respectively in the control;serum LN,PCⅢ and HA levels were（126.3±29.0） μg/L,（212.3±43.8）μg/L and （211.4±42.0） μg/L,significantly lower than【（140.3±32.1） μg/L,（267.5±39.8） μg/L and（329.6±68.4） μg/L,P<0.05】,respectively in the control;the LSM was （13.6±2.4）kPa,much lower than 【（17.6±5.2）kPa,P<0.05】 in the control;at the end of 24 week follow-up,the serum ALT normalization and sustained virologic response（SVR） in the observation group were much higher than those in the control（93.4% vs. 45.9% and 72.1% vs. 9.8%,respectively,P<0.05）,and disease progression was 3.3%,much lower than 13.1% （P<0.05） in the control. Conclusion The application of pe-IFN-α2a and ribavirin combination in treatment of patients with compensated hepatitis C liver cirrhosis is efficient, which might significantly increase serum ALT normalization,improve SVR and postpone the disease progression.

Key words: Liver cirrhosis, Hepatitis C, Pegylated interferon-α-2a, Ribavirin, Therapy